HTA224 Commissioning Through Evaluation: RWE for Rituximab in the Management of Idiopathic Membranous Nephropathy
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1682
https://www.valueinhealthjournal.com/article/S1098-3015(22)03887-6/fulltext
Title :
HTA224 Commissioning Through Evaluation: RWE for Rituximab in the Management of Idiopathic Membranous Nephropathy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03887-6&doi=10.1016/j.jval.2022.09.1682
First page :
Section Title :
Open access? :
No
Section Order :
11236